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Structured abstract 
Purpose of review  
We review the recent advances in the initial approach to resuscitation of sepsis and septic shock 
patients. 
Recent findings 
Sepsis and septic shock are life threatening emergencies. Two key interventions in the first hour 
include timely antibiotic therapy and resuscitation. Before any laboratory results, the need for 
resuscitation is considered if a patient with suspected infection has low blood pressure or impaired 
peripheral circulation found at clinical examination. Until now, this early resuscitation in sepsis and 
septic shock was supported by improvements in outcome seen with goal-directed therapy. However, 
three recent, goal-directed therapy trials failed to replicate the originally reported mortality reductions, 
prompting a debate on how this early resuscitation should be performed. As resuscitation if often 
focussed on macrociculatory goals such as optimising central venous pressure, an argument to 
explore for lack of outcome benefit in the newer trials is the discordance between microcirculatory and 
macrocirculatory optimisation during resuscitation. Vasoactive drugs and large volume resuscitation 
associated positive fluid balance, are independently associated with worse clinical outcomes in 
critically ill sepsis and septic shock patients. As lower blood pressure targets and restricted volume 
resuscitation are feasible and safe, should we use a revised blood pressure target to reduce the 
adverse effects of catecholamine’ and excess resuscitation fluids. Evidence guiding fluids, 
vasopressor and inotrope selection remains limited. 
Summary 
Though the early resuscitation of septic shock is key to improving outcomes, ideal resuscitation 
targets are elusive. Distinction should be drawn between microcirculatory and macro-circulatory 
changes, and corresponding targets. Common components of resuscitation bundles such as large 
volume resuscitation and high-dose vasopressors may not be universally beneficial. Microcirculatory 
targets, individualised resuscitation goals and reassessment of completed trials using the updated 
septic shock criteria should be focus areas for future research. 
 
Key words: Sepsis, septic shock, resuscitation, microcirculation
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Septic shock resuscitation in the first hour 
Introduction 
Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to 
infection(1). In this context, the organ dysfunction is identified clinically by an increase in the 
Sequential [Sepsis-related] Organ Failure Assessment (SOFA) score of 2 points or more(1, 2). Septic 
shock is defined as a subset of sepsis in which particularly profound circulatory, cellular, and 
metabolic abnormalities are associated with a greater risk of mortality than with sepsis alone(1). The 
clinical criteria for identifying septic shock patients is a vasopressor requirement to maintain a mean 
arterial pressure of 65 mmHg or greater and serum lactate level greater than 2 mmol/L (>18 mg/dL) in 
the absence of hypovolemia(3). Resuscitation is the key intervention for treating macro and 
microcirculatory abnormalities commonly observed in sepsis and septic shock patients(4) and 
resuscitation also forms part of the 3-hour and 6-hour bundles proposed in the Surviving Sepsis 
Campaign Guidelines(5). In this review, we discuss sepsis related microcirculation and macro-
circulation abnormalities, resuscitation goals in guidelines, microcirculation as a focus of early 
resuscitation, and emerging evidence on fluids, vasoactive active drugs and adjuvants targeted during 
resuscitation in sepsis and septic shock. 
Microcirculation and macro-circulation abnormalities are common in sepsis 
and septic shock 
Microcirculation refers to circulation within the blood vessels less than 100 to 150 micrometer in 
diameter (such as arterioles, capillaries, venules, and lymphatics) and the associated cells such as 
endothelium, smooth muscle, erythrocytes, leukocytes and platelets. The tools required to measure 
microcirculatory flow directly are not routinely available. Notwithstanding, tissue perfusion based 
markers(6) such as lactate, mixed / central venous oxygen saturation (ScvO2), and central venous-
arterial partial pressure of carbon dioxide difference (DeltaPCO2)(7, 8), constitute indirect markers of 
adequate global microcirculation. Microcirculation could also be assessed to understand the 
homogeneity in blood flow by assessing number of patent capillaries, referred to as functional 
capillary density’ [FCD].  
In sepsis, the microcirculation is profoundly altered due to local and systemic host responses. The 
endothelial barrier is altered from it natural continuous and anticoagulant barrier between circulating 
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blood and tissue into a disrupted barrier that is enhances coagulation, extravasation of fluids and 
activated leukocytes creating a vicious cycle. This perpetuates inflammation, coagulopathy and 
endothelial injury(9). The associated impaired vascular smooth muscle tone, relative hypovolemia and 
a reduction in the FCD results in a heterogeneous combination of microcirculatory units lose their 
ability to regulate vascular tone and inappropriately constricted arterioles coexist with vasodilated 
units. These changes result in inefficient microcirculation resulting in an oxygen partial pressure (PO2) 
gap evidenced by the reduced capillary PO2, increased venous PO2 and impaired mitochondrial 
oxygen extraction(10, 11).  
The circulation in larger blood vessels is referred to as macro-circulation. Indicators of macro-
circulation include central venous pressure (CVP), pulmonary wedge pressure (PAWP), arterial blood 
pressure (ABP), cardiac output (CO), arterial oxygen content (CaO2) and delivery (DO2). Similar to 
microcirculatory changes, the macrocirculation abnormalities in sepsis are also heterogeneous. In 
addition, there is an acute reversible myocardial depression affecting both ventricles, with altered 
myocytes and gene expression abnormalities suggestive of impaired sarcomere contraction and 
impaired excitation-contraction coupling(12, 13). 
Early resuscitation in sepsis and septic shock  
In 2001, Rivers et al, reported a 263 patient single centre randomised controlled trial (RCT) of early 
goal-directed therapy (EGDT) versus standard care for patients with severe sepsis or septic shock, 
that showed 16% absolute reduction in in-hospital mortality with EGDT. This EGDT consisted of firstly 
achieving the macro-circulation goals (CVP>=8-12mmHg, MAP>=65mmHg), followed by the 
microcirculation target of ScvO2>=70%. The interventions to achieve these macro-circulation goals 
were fluids and vasopressors and those for microcirculation goals were red blood transfusion to a 
haemoglobin >10g/L and/or inotropic agents to improve cardiac output. The key differences between 
the EGDT arm and usual care arm in term of interventions administered between 0 hours and 6 hours 
were – significantly greater volume of fluids, red blood cells, and inotropic agents. This trial formed the 
basis for the resuscitation goals in the previous Surviving Sepsis Campaign Guidelines(14). Goals 
during the first 6 hours of resuscitation: CVP = 8–12; MAP ≥ 65 mm Hg; urine output ≥ 0.5 
mL/kg/hr and ScvO2 (superior vena cava) or mixed venous oxygen saturation >=70% or 65%, 
respectively.  
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Between 2008 and 2014, three further multicentre RCTs compared EGDT to usual care, using a 
similar protocol to Rivers et al, enrolling a total of 4211 patients, from the United States (Protocolized 
Care for Early Septic Shock [ProCESS]), Australasia (Australasian Resuscitation in Sepsis Evaluation 
[ARISE]), and the United Kingdom (Protocolised Management in Sepsis [ProMISe]). In addition to trial 
level meta-analyses (15), the authors also harmonised data from these three trials and reported an 
individual patient level meta-analysis (IPDMA) (16), to explore the overall average treatment effect 
and key pre-defined subgroups effects of EGDT compared to usual care. The 90-day mortality did not 
differ between the EGDT therapy (24.9%) and usual care (25.4%) groups with a non-significant 
adjusted odds ratio (95% confidence interval) of 0.97 (0.82 – 1.14). The EGDT treatment effect did 
not vary by severity of illness. Based on these results, the current Surviving Sepsis Campaign 
Guidelines(5) strongly recommend administering at least 30 mL/kg of intravenous crystalloid fluids 
within the first 3 hours, whilst acknowledging that this is based on low quality of evidence). These 
guidelines also recommend a target MAP>=65mmHg and suggest guiding resuscitation to normalize 
lactate in patients with elevated lactate levels, which is a weak recommendation based on low quality 
evidence, but addresses a microcirculation goal. 
Is there a role for targeting microcirculation during early resuscitation? 
The microcirculation goals addressed in RCTs include a reduction in serum lactate concentrations 
compared to either ScvO2 in the emergency department (The LactATES trial (17)) or to usual care in 
the ICU (18). The LactATES trial was a non-inferiority RCT in 300 patients and compared the control 
group who received targeted resuscitation to meet thresholds of CVP, followed by MAP, and then 
ScvO2 of 70% or more to the lactate clearance group that had similar targeted thresholds in CVP, 
MAP, and then lactate clearance of 10% or more. This trial highlighted that lactate clearance is non-
inferior to ScvO2 based resuscitation. Of note, a pre-specified subgroup analysis from this trial 
highlighted that achievement of only the ScvO2 goal was associated with a higher mortality compared 
to achievement of only the lactate clearance goal only (41% vs 8% and difference in proportion = 
33%; 95% CI = 9% to 55%). Whilst these underpowered subgroup analyses needs testing in RCTs 
prior to clinical adoption(19), it does highlight the value of studying lactate kinetics. In the ICU, Jansen 
et al evaluated a complex protocol to target a lactate clearance of 20% or more. Although, there was 
no difference in unadjusted mortality between the usual care arm and lactate clearance arm, the 
covariate adjusted OR was significantly lower in the lactate clearance arm. Patients in the lactate 
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clearance arm received more fluids and, as stipulated by the experimental protocol, 42.5% received 
vasodilators during the first eight hours of resuscitation with the objective of 'opening' microcirculatory 
units. This approach challenges the more traditional goals of resuscitation (e.g. MAP of 65 mmHg). 
Vasopressors, which are commonly used to achieve MAP targets, could be reduced to the extent that 
minimal perfusion can be maintained at lower MAP values and, ultimately, administering vasodilators 
therapy could improve microcirculatory flow. However, while lactate clearance is undisputedly a 
favourable prognostic sign(20), high lactate levels are not specific for tissue dysoxia in sepsis and 
catecholamines’ directly increase lactate levels via increased glycolysis(21). Furthermore, the 
Surviving Sepsis Campaign guideline panel made a weak recommendation for lactate-guided 
resuscitation protocols, based on low quality evidence, and did not address vasodilators, citing 
methodological limitations in the supporting literature.  
Arteriovenous CO2 gradients constitute another potential resuscitation target(22). In theory, the 
difference between venous and arterial carbon dioxide blood content increases in proportion with the 
mismatch between cardiac output and the production of carbon dioxide. Elevated DeltaPCO2 
gradients (the normal range is 2-6 mmHg) may indicate inadequate blood flow relative to metabolism 
before lactate levels rise. However, CO2 metabolism is complex and the value of DeltaPCO2 gradients 
as resuscitation targets hinges on numerous assumptions. Moreover, the overall effects of 
resuscitation protocols guided by DeltaPCO2 gradients remain unknown. Finally, in a provocative 
study, Marik and colleagues highlight the potential clinical benefits of combined early administration of 
intravenous vitamin C, together with corticosteroids and thiamine with biological plausibility arguments 
that point towards the microvasculature effects of this intervention(23). In summary, well designed 
and adequately powered experiments on the role of microvascular resuscitation in sepsis and septic 
shock patients are urgently needed. 
Fluids 
The theoretical goal of administration of fluid in the initial resuscitation of septic shock is the 
restoration of stressed intravascular volume and optimization of ventricular preload. The amount and 
type of fluid therapy remain contentious. Whilst fluid boluses may augment immediate haemodynamic 
parameters, concerns exist in regard to the transient nature of effect, the impact on the 
microcirculation and risk of iatrogenic complications (24-26). There remains a similar lack of clarity 
around the most appropriate type of fluid to administer in the early phases of resuscitation in septic 
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shock. Hydroxyethyl starch solutions are no longer widely recommended based on a lack of overall 
benefit and potential harm (27). Similarly, the potential efficacy signal in the sepsis subgroup for 
Albumin based resuscitation could not be confirmed in a recent RCT(28). In the absence of any 
clearly demonstrated benefit for colloids, initial crystalloid resuscitation is still recommended in the 
2016 Surviving Sepsis guidelines, although concerns persist about the multiple potential side effects 
of resuscitation with normal saline including renal, pro-inflammatory, anticoagulant and acid-base 
associations. Balanced solutions have theoretical advantages, although a clear benefit is yet to be 
consistently demonstrated(12). Whichever fluid and volume is chosen, with limited and conflicting 
evidence in the setting of septic shock, it is important that the therapeutic agent is considered a drug, 
and administered with such caution.  
Large volumes of resuscitation fluids administered to septic shock patients result in a positive 
cumulative fluid balance. This increasing cumulative balance impairs microcirculation and is an 
independent risk factor for mortality in sepsis and septic shock patients(29, 30). Furthermore, in 
children with severe infection, when either saline or albumin fluid boluses were administered over and 
above the maintenance fluids, the 48-hour mortality was significantly higher(31). These observations 
resulted in a feasibility RCT of conservative versus liberal approach to fluid therapy in septic shock 
(CLASSIC Trial). This trial highlighted feasibility for this approach with significantly lower cumulated 
resuscitation fluid in the ICU at day 5 after randomisation and during the entire ICU stay in the 
restriction group vs. the standard care group [mean differences −1.2 L (95 % CI −2.0 to −0.4); and 
−1.4 L (95 % CI −2.4 to −0.4); P < 0.001) without increasing the risk of adverse outcomes(32). A initial 
approach involving passive leg raising to assess fluid responsiveness may reduce the total volume of 
fluid administered in sepsis and septic shock patients(33). 
Vasopressors and inotropic agents 
Vasopressors, like fluids, are an intuitive component of resuscitation bundles. In theory, vasopressors 
correct excessive vasodilatation at the root of the alleged pathological causal pathway. However, 
hypotension does not necessarily signify impaired organ perfusion and normal blood pressure does 
not guarantee adequate tissue perfusion. By Poiseuille's law, the blood vessel's radius has a much 
more profound impact on flow than the pressure gradient. Because vasopressors induce 
vasoconstriction (i.e. reducing the radius of vessels), they may reduce organ perfusion despite 
achieving blood pressure targets. In addition, vasopressors themselves may impair microcirculatory 
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flow(34). For example, clinicians may be inclined to attribute worsening signs of shock to the 
underlying illness and intensify therapy, unsuspecting of the fact that it is their intervention that is the 
culprit. Accordingly, when administering vasoactive agents, clinicians should consider iatrogenic 
complications in the differential diagnosis of any clinical deterioration. Recent studies raise concern 
regarding the overall safety of liberal vasopressor use in sepsis. Until adequately powered clinical 
trials ascertain the overall effects of more restrictive MAP targets, the overall benefit of currently 
recommended MAP targets hinges on scant evidence(35).  
When discussing vasopressor therapy, the role of relative vasopressin deficiency and utility of 
vasopressin as a vasopressor in septic shock have to be considered(36). In a trial of vasopressin 
versus norepinephrine and steroids versus placebo, using a factorial trial design, with renal failure 
free days as primary outcome, vasopressin compared with norepinephrine did not improve the 
number of kidney failure–free days(37). The hypothesis from sub-group analyses from earlier 
vasopressin trials(38), is that patients with lower severity of illness may benefit the most. This 
hypothesis should be tested in the context of increasing vasopressin use in patients with septic 
shock(39). The circulatory changes in sepsis could also be secondary to abnormalities in the renin-
angiotensin system and exogenously administered exogenous angiotensin II could be an useful 
vasopressor in septic shock patients(40). Recently, in patients with catecholamine resistant 
vasodilatory shock, angiotensin II administration was associated with improved blood pressure, which 
was the primary outcome. In this trial, nearly 75% of patients the aetiology of catecholamine resistant 
vasodilatory state was septic shock, implying potential utility for angiotensin II in septic shock 
management, once mortality benefit is confirmed(41).    
Levosimendan is a calcium-sensitising drug that has multiple effects aside from positive inotropy, 
which are potentially beneficial in sepsis. For example, in a recent pilot randomised controlled trial in 
20 patients, levosimendan lowered the lactate/pyruvate ratio, which suggests beneficial effect on 
cellular metabolic alterations in septic shock(42). However, a large superiority trial that tested the 
hypothesis that levosimendan would reduce the severity of organ dysfunction in adults with sepsis, in 
516 adult patients with sepsis, levosimendan compared to placebo was not associated with less 
severe organ dysfunction or lower mortality. Importantly there was a higher risk of supraventricular 
arrhythmias and weaning failure in the levosimendan treated patients in this trial(43). Given the lack of 
efficacy of levosimenden in cardiac surgical patients with impaired left ventricular function(44, 45), 
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further studies to enrich sepsis population that is likely to benefit from levosimenden is required prior 
to widespread clinical use. 
Conclusions 
Septic shock is common and carries a high risk of death. Early administration of antibiotics and 
targeted resuscitation remain the cornerstones of care. There is increasing evidence that some 
conventional approaches with large volume resuscitation and high-dose vasopressors may not be 
beneficial, or even potentially harmful. Distinction should be drawn between microcirculatory and 
macro-circulatory changes and resuscitation. Individualised resuscitation focused on microcirculation 
and lower blood pressure targets may have theoretical advantages over macro-circulatory goals of 
care applied invariably to all patients. However, conclusive evidence will require adequately powered 
experiments.  
 
Key points 
The Surviving sepsis campaign guidelines provide a framework for managing sepsis patients. 
Early antibiotic therapy and fluid resuscitation are major interventions in sepsis patients. 
Emerging evidence suggests discordance between macrocirculatory and microcirculatory optimisation 
following resuscitation.  
As resuscitation-associated, positive fluid balance and high dose vasopressors are associated with 
adverse outcomes in septic shock, trials of fluid restriction and lower blood pressure targets are 
ongoing. 
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